Michael Hall Cancer Survivor Story
– Michael Hall was born on February 1, 1971, in Raleigh, North Carolina.
– His father died of prostate cancer in 1982, when Hall was eleven years old.
– He is known for his roles as Dexter Morgan, in TV Network series Dexter and as David Fisher in the HBO drama series Six Feet Under.
– In 2010, He won a Golden Globe Award and a Screen Actors Guild Award for his role in Dexter.
– On January 13, 2010, Hall’s agent and the spokesman confirmed that Hall was undergoing treatment for a form of Hodgkin’s lymphoma.
– After undergoing Chemotherapy for 3 months. On April 25, 2010, It was announced that Hall’s cancer was fully in remission.
-He then started working for the next season of Dexter.
– In 2011, Hall was the celebrity spokesperson for the Leukemia & Lymphoma Society’s “Light the Night Walk” fundraising campaign.
– If he can do it, you can too.
More about Hodgkin’s Lymphoma
Hodgkin’s Lymphoma mainly arises from the B-cells. It may involve any part of the lymphatic system, but it usually starts in lymph nodes in the neck, under the arms, and in the chest.
According to WHO classification, HL can be divided into following 2 main types:
- Classic Hodgkin lymphoma (CHL): This is the most common type of HL that comprises about 95% of all HL cases in the western countries. The characteristic feature of CHL is the presence of Reed-Sternberg cells (abnormal B-cells) in a background of inﬂammatory and accessory cells such as eosinophils, neutrophils, histiocytes, plasma cells, and fibroblasts. The Reed-Sternberg cells of CHL usually express CD30, CD15, and variably CD20 surface markers.
CHL is further divided into following 4 subtypes:
a) Nodular sclerosis Hodgkin lymphoma (NSCHL)
b) Mixed cellularity Hodgkin lymphoma (MCCHL)
c) Lymphocyte-rich Hodgkin lymphoma
d) Lymphocyte-depleted Hodgkin lymphoma
- Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): This is a relatively less common type of HL comprising about 5% of all cases of HL. The characteristic feature of NLPHL is the presence of “popcorn” or lymphocyte-predominant (LP) cells, the variant of Reed-Sternberg cells. The LP cells usually express CD45, CD20, and rarely CD30 surface markers. The NLPHL is inherently slow-growing compared to HL and is treated slightly differently than HL.
Ann Arbor is the staging system used for Hodgkin’s Lymphoma in which it is staged from Stage 1 to Stage 4 depending on the extent of involvement.
Lymph node biopsy, Imaging, and Blood tests are investigations required for confirmation of the diagnosis and disease staging.
Hodgkin’s lymphoma treatment depends on the type of HL, stage of the disease, patient’s age, and performance status, the presence of adverse prognostic factors, along with other factors.